Trials / Completed
CompletedNCT03025945
Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo
Pseudophakic Cystoid Macular Edema Prevention and Risk Factors; Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 662 (actual)
- Sponsor
- Intuor Technologies, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Prospective, randomized, double-masked, placebo-controlled clinical study to define the effective use of a topical non-steroidal anti-inflammatory drug added to topical steroid use after uncomplicated phacoemulsification for the prevention of pseudophakic cystoid macular edema.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nepafenac 0.3% | |
| DRUG | Saline Solution |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2017-01-01
- Completion
- 2017-01-01
- First posted
- 2017-01-20
- Last updated
- 2018-12-14
- Results posted
- 2018-12-14
Source: ClinicalTrials.gov record NCT03025945. Inclusion in this directory is not an endorsement.